What is Lee's Pharmaceutical Holdings Enterprise Value?
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Lee's Pharmaceutical Holdings Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Lee's Pharmaceutical Holdings Enterprise Value Chart
Competitive Comparison of Lee's Pharmaceutical Holdings's Enterprise Value
For the Drug Manufacturers - Specialty & Generic subindustry, Lee's Pharmaceutical Holdings's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lee's Pharmaceutical Holdings's Enterprise Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lee's Pharmaceutical Holdings's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Lee's Pharmaceutical Holdings's Enterprise Value falls into.
Lee's Pharmaceutical Holdings Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lee's Pharmaceutical Holdings (HKSE:00950) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Lee's Pharmaceutical Holdings's EV-to-EBIT for today is
Lee's Pharmaceutical Holdings's current Enterprise Value is HK$803 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Lee's Pharmaceutical Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was HK$112 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Lee's Pharmaceutical Holdings's EV-to-EBITDA for today is:
Lee's Pharmaceutical Holdings's current Enterprise Value is HK$803 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Lee's Pharmaceutical Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was HK$112 Mil.
Lee's Pharmaceutical Holdings's current Enterprise Value is HK$803 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Lee's Pharmaceutical Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was HK$1,400 Mil.
Lee's Pharmaceutical Holdings's current Enterprise Value is HK$803 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Lee's Pharmaceutical Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was HK$34 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lee's Pharmaceutical Holdings Enterprise Value Related Terms
Thank you for viewing the detailed overview of Lee's Pharmaceutical Holdings's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Lee's Pharmaceutical Holdings Business Description
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:00950 has been successfully added to your 